Menu Back toBasics of Healthcare Reform for Lifesciences Professionals
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
DIA 2021 Global Annual Meeting
Basics of Healthcare Reform for Lifesciences Professionals
Mitchell Berger, JD, MPH, RAC
- Public Health Advisor
- HHS, United States
This forum provides an overview of healthcare reform basics for pharmaceutical industry staff amid the ongoing impact of COVID-19 and calls for health equity. Topics discussed include major US health care programs, pharmaceutical pricing and innovation models.
Learning Objective : Summarize major health care programs of interest to the pharmaceutical industry such as Medicare and Medicaid; Describe recent steps by federal and state governments to promote innovation; Discuss drug pricing and how ongoing health system delivery reform changes, such as value-based design and comparative effectiveness may impact the pharmaceutical industry.
Potential Health Reform Approaches (e.g., Public Option, Medicare for All)
Ed Weisbart, MD, FAAFP
- Chair, MO Chapter
- Physicians for a National Health Program, United States
Overview of Drug Pricing (US)
Barry Berger, JD, MBA
- Former Professor of Regulatory Affairs, Temple University, United States
CMS Innovation Models
Rebecca Yip, MS
- Avalere Health, United States